Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Innovent Biologics, Inc.
  6. Summary
    1801   KYG4818G1010

INNOVENT BIOLOGICS, INC.

(1801)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
77.75 78 77.3 76.9 76.65 Last
3786773 2582082 2593769 3264485 2740387 Volume
+1.30% +0.32% -0.90% -0.52% -0.33% Change
Estimated financial data (e)
Sales 2021 4 228 M 662 M 662 M
Net income 2021 -1 569 M -246 M -246 M
Net cash position 2021 5 918 M 927 M 927 M
P/E ratio 2021 -58,9x
Yield 2021 -
Sales 2022 6 419 M 1 005 M 1 005 M
Net income 2022 -670 M -105 M -105 M
Net cash position 2022 5 020 M 786 M 786 M
P/E ratio 2022 -142x
Yield 2022 -
Capitalization 91 895 M 14 394 M 14 395 M
EV / Sales 2021 20,3x
EV / Sales 2022 13,5x
Nbr of Employees 4 596
Free-Float 92,6%
More Financials
Company
Innovent Biologics, Inc. is a China-based biopharmaceutical company. The Company’s main products include PD-1 antibody; bevacizumab (Avastin) biosimilar, IBI-305; rituximab (MabThera/Rituxan) biosimilar, IBI-301; and adalimumab (Humira) biosimilar, IBI-303. 
Sector
Pharmaceuticals
Calendar
04/04Earnings Release
More about the company
Ratings of Innovent Biologics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about INNOVENT BIOLOGICS, INC.
10/18Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutat..
CI
10/17INNOVENT BIOLOGICS : Bio's Phase 3 Study of Lung Cancer Combination Therapy Yields Positiv..
MT
10/13ASCENTAGE PHARMA INTERNATIONAL : Concludes Issuance of Nearly 7 Million Warrants to Innove..
MT
09/30Innovent Biologics, Inc. Announces the First Patient Dosed in the Phase I/II Study of I..
CI
09/29GenFleet Therapeutics and Innovent Biologics Starts First-in-human Phase I/II Trial of ..
CI
09/29Innovent Releases Preliminary Results of the Phase Ia Dose-Escalation study of IBI315 (..
CI
09/27INNOVENT BIOLOGICS : Bio Pays $20 Million to Secure China Rights to Union Therapeutics' Ps..
MT
09/27Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-..
CI
09/24Innovent Announces First Patient Dosed in A Phase 2 Clinical Trial of IBI112 (IL-23 Mon..
CI
09/23Innovent Biologics, Inc. Announces NMPA Acceptance of a Supplemental New Drug Applicati..
CI
09/22INNOVENT BIOLOGICS : Wins Regulatory Nod in China for Supplemental New Drug Application fo..
MT
09/22The National Medical Products Administration Accepts the Supplemental New Drug Applicat..
CI
09/18Iinnovent Biologics, Inc. Announces That the Interim Analysis Results of the Phase 3 Or..
CI
09/17Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Chol..
CI
09/15China's biotech sector comes of age with big licensing deals, global ambitions
RE
More news
News in other languages on INNOVENT BIOLOGICS, INC.
10/17L'étude de phase 3 d'Innovent Bio sur la thérapie combinée contre le cancer du poumon d..
09/27Innovent Bio verse 20 millions de dollars pour obtenir les droits sur le médicament con..
09/22Innovent Biologics obtient le feu vert réglementaire en Chine pour une demande suppléme..
09/01Innovent Biologics obtient un accord de licence pour un inhibiteur de tumeur expériment..
04/23Pump / dump #8
More news
Analyst Recommendations on INNOVENT BIOLOGICS, INC.
More recommendations
Chart INNOVENT BIOLOGICS, INC.
Duration : Period :
Innovent Biologics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNOVENT BIOLOGICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 62,95 CNY
Average target price 78,75 CNY
Spread / Average Target 25,1%
EPS Revisions
Managers and Directors
De Chao Yu Chairman & Chief Executive Officer
Yong-Jun Liu President
Hao Xi Ede Chief Financial Officer & Executive Director
Jessie Chen Chief Medical Officer
Qin Wei Zhou Chief Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
INNOVENT BIOLOGICS, INC.-6.58%14 394
CSL LIMITED4.48%100 729
WUXI BIOLOGICS (CAYMAN) INC.10.21%61 841
SAMSUNG BIOLOGICS CO.,LTD.6.54%49 427
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.8.14%39 464